← All trials
NCT06607380
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2022
- Primary completion
- Apr 10, 2023
- Completion date
- Apr 17, 2023
- First posted
- Sep 23, 2024
- Last posted
- Sep 23, 2024
- Enrollment
- 60
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Guangzhou Trinomab Biotech Co., Ltd.Lead sponsor
- Peking UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.